ASX Announcement
18 November 2026

Results of Annual General Meeting

Sydney, Australia – 18 November 2026: OncoSil Medical Limited (ASX: OSL), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC) and distal cholangiocarcinoma (dCCA), advises that all resolutions considered at the Annual General Meeting held today were carried by poll.

In accordance with ASX Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, details of the proxies received and votes cast in respect of each resolution are attached.

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 160 9642 4981	**Mr. Tim Luscombe & Ms. Nova Taylor** Joint Company Secretaries E: tim.luscombe@bio101.com & nova.taylor@bio101.com T: +61 429 707 079 & +61 414 877 703

About OncoSil Medical

OncoSil Medical (ASX) is a global medical device company focused on Interventional Oncology, with a mission to improve outcomes for people living with pancreatic cancer. The company has developed OncoSil™, a single-use brachytherapy (internal radiation) device that delivers a pre-determined dose of beta radiation directly into cancerous tissue using targeted intratumoural placement of Phosphorous-32 (^{32}P) Microparticles. Its targeted approach enables a greater radiation dose to be delivered directly to the tumour while limiting exposure to surrounding critical organs.

In the United States, OncoSil™ is indicated for the treatment of patients with distal cholangiocarcinoma (dCCA) that is both unresectable (locally advanced and/or unfit for surgery) and non-metastatic, as an adjunct to systemic therapy. In markets outside the United States where OncoSil™ has received regulatory approval, OncoSil™ is indicated for the treatment of patients with unresectable locally advanced pancreatic cancer, in addition to gemcitabine-based chemotherapy.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year[1]. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival. Distal cholangiocarcinoma (dCCA) is a rare form of bile duct cancer. It is often diagnosed at an advanced stage, when surgical treatment may no longer be possible, and is associated with a poor prognosis.

OncoSil™ has received CE Marking approval, providing marketing authorisation in the European Union and the United Kingdom. OncoSil™ has also received approval from the U.S. Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE) for the treatment of patients with unresectable, non-metastatic distal cholangiocarcinoma (dCCA), as an adjunct to systemic therapy. OncoSil™ has been designated as a Breakthrough Device in Europe and the United States. It is currently approved for sale in 30+ countries, including the European Union, United Kingdom, United States, Australia, Saudi Arabia, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

[1] https://gco.iarc.fr/en

Results of Meeting

OncoSil Medical Ltd

Annual General Meeting

Wednesday, 18 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 ADOPTION OF REMUNERATION REPORT	P	16,672,924 99.57%	66,526 0.40%	21,883	5,473 0.03%	16,678,397 99.60%	66,526 0.40%	21,883	-
2 RE-ELECTION OF MS LELDE SMITS	P	16,939,045 99.92%	7,457 0.04%	13,224	5,473 0.03%	16,944,518 99.96%	7,457 0.04%	13,224	Carried
3 APPROVAL OF OMNIBUS PLAN	P	16,651,377 99.63%	57,356 0.34%	52,804	5,269 0.03%	16,656,646 99.66%	57,356 0.34%	52,804	Carried
4 APPROVAL OF ISSUE OF OPTIONS TO MR NIGEL LANGE	P	16,637,884 99.41%	94,983 0.57%	30,779	3,160 0.02%	16,641,044 99.43%	94,983 0.57%	30,779	Carried
5 APPROVAL OF ISSUE OF OPTIONS TO DR THOMAS DUTHY	P	16,650,913 99.47%	81,857 0.49%	26,779	7,257 0.04%	16,658,170 99.51%	81,857 0.49%	26,779	Carried
6 APPROVAL OF ISSUE OF OPTIONS TO MS LELDE SMITS	P	16,654,153 99.49%	78,617 0.47%	26,779	7,257 0.04%	16,661,410 99.53%	78,617 0.47%	26,779	Carried
7 APPROVAL OF 10% PLACEMENT FACILITY	P	16,565,112 97.65%	389,302 2.29%	1,200	9,585 0.06%	16,574,697 97.71%	389,302 2.29%	1,200	Carried
8 RATIFICATION OF PRIOR ISSUES OF PLACEMENT SHARES	P	16,891,656 99.59%	60,066 0.35%	3,892	9,585 0.06%	16,901,241 99.65%	60,066 0.35%	3,892	Carried